Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Hearing Loss
Interventions: Standard School Screening and Referral, Enhanced mHealth Screening, Specialty Telemedicine Referral; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 3 Years to 11 Years
Enrollment: 18,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: SCHIZOPHRENIA 1 (Disorder), Nicotine Use
Interventions: iTBS to the DMN, cTBS to the DMN, Sham rTMS; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Environmental Exposure, PFAS Exposure
Interventions: Streptococcus salivarius 46-SL1, Placebo; Dietary Supplement
Lead sponsor: Cambiotics ApS; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV/AIDS
Interventions: Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV); Drug
Lead sponsor: International Partnership for Microbicides, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Drug Abuse
Interventions: Ramelteon, triazolam, and placebo (56 possible combinations total); Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Liver Cancer, Cancer of the Liver
Interventions: 4Dimensional Phase Contrast Magnetic Resonance Angiography, Portal vein embolization; Device · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes Prevention
Interventions: Dose 1, Dose 2, Dose 0, Dose 3, Dose 4, Dose 5, Dose 6; Dietary Supplement
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Healthy Volunteers
Interventions: Brensocatib, Rifampin, Esomeprazole; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Asthma
Interventions: Placebo twice daily, Olodaterol low daily dose twice daily, Olodaterol medium daily dose twice daily, Olodaterol high daily dose once daily and placebo, Olodaterol medium daily dose once daily and placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 12
States / cities: Huntington Beach, California • Centennial, Colorado • Wheat Ridge, Colorado + 9 more

Conditions: Heparin-induced Thrombocytopenia
Interventions: VLX-1005, Argatroban; Drug
Lead sponsor: Veralox Therapeutics; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Schizophrenia Disorder, Schizophreniform Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified (NOS)
Interventions: Plasma NDE miRNA Sequencing, Whole Genome Sequencing; Diagnostic Test · Genetic
Lead sponsor: Northwell Health; Other
Eligibility: 15 Years to 40 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Lung Cancer
Interventions: cisplatin, irinotecan hydrochloride, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 49
States / cities: Birmingham, Alabama • Burbank, California • Hayward, California + 39 more

Conditions: Healthy, Traumatic Brain Injury
Interventions: NeuroCatch Platform (NCP); Device
Lead sponsor: Frederick Carrick, PhD, FACCN; Other
Eligibility: 14 Years to 25 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cape Cañaveral, Florida

Conditions: Type 2 Diabetes Mellitus
Interventions: 2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Oxygen Saturation
Interventions: Finger hyperperfusion via adenosine, Finger hypoperfusion via by norepinephrine, Baseline hypoxic test; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Subjects
Interventions: CPI-444 Capsules, CPI-444 Tablets; Drug
Lead sponsor: Corvus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypoglycemia
Interventions: Glucagon for Injection (Fresenius Kabi USA), Glucagon for Injection (Bedford Laboratories); Drug
Lead sponsor: Fresenius Kabi USA, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: Rifampin, Canagliflozin; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Mental Health Issue, Parent-Child Relations
Interventions: LGBTQ-affirmative CBT, ABFT-SGM; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 20 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: TERA Intervention (TERA), Standard of Care (SOC); Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 13 Years to 24 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: Aurora, Colorado • Fort Lauderdale, Florida • Jacksonville, Florida + 5 more

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Placebo, AZD0780; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 26
States / cities: Inglewood, California • Northridge, California • Pomona, California + 20 more

Conditions: HIV Infections
Interventions: GSK3640254, DTG, GSK3640254/DTG; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: HIV, Sexually Transmitted Infections
Interventions: Multimedia WORTH, Traditional WORTH, Wellness Promotion; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 306 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Male Subjects
Interventions: Savolitinib, Fluvoxamine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Search by objective public record fields.

School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Kentucky

Behavioral Impact and Neural Correlates of Network-based Brain Stimulation in Schizophrenia

Effect of a Dietary Supplement Versus Placebo on Serum PFAS Levels in Male Firefighters

Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults

Behavioral and Subjective Efficacy of Ramelteon in Subjects With a History of Polydrug Abuse

4D Phase Contrast MR: Hypertrophy in Liver Cancer

Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.)

A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma

A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects

MicroRNAs as Biomarkers in First Episode Schizophrenia

Chemotherapy Combined With Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Investigating Event-Related Potentials and Eye-Tracking Measures in Hockey Players

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Hand Perfusion and Pulse Oximetry Performance

Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects

Bioequivalence of Fresenius Kabi USA, LLC Glucagon for SC Injection Compared to Glucagon for Injection (Bedford Laboratories)

A Study to Evaluate the Effects of Rifampin on Single-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers

Affirmative Family and Individual Psychotherapy for Sexual and Gender Minority Adults and Their Nonaccepting Parents

Triggered Escalating Real-time Adherence (TERA) Intervention

A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure

A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants

The Multimedia HIV/STI Prevention for Drug-Involved Female Offenders

A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects